Therapeutic options for visceral leishmaniasis

73Citations
Citations of this article
147Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Visceral leishmaniasis (VL), also known as Kala-Azar, is a disseminated protozoal infection caused principally by Leishmania donovani and Leishmania infantum (known as Leishmania chagasi in South America). The therapeutic options for VL are diverse and depend on different factors, such as the geographical area of the infection, development of resistance to habitual treatments, HIV co-infection, malnourishment and other concomitant infections. This article provides an exhaustive review of the literature regarding studies published on the treatment of VL, and gives therapeutic recommendations stratified according to their level of evidence, the species of Leishmania implicated and the geographical location of the infection. © The Author(s) 2013.

Cite

CITATION STYLE

APA

Monge-Maillo, B., & López-Vélez, R. (2013, November). Therapeutic options for visceral leishmaniasis. Drugs. https://doi.org/10.1007/s40265-013-0133-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free